<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>건강과 대안 &#187; Prion</title>
	<atom:link href="http://www.chsc.or.kr/tag/Prion/feed" rel="self" type="application/rss+xml" />
	<link>http://www.chsc.or.kr</link>
	<description>연구공동체</description>
	<lastBuildDate>Mon, 13 Apr 2026 01:34:28 +0000</lastBuildDate>
	<language>ko-KR</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.5.2</generator>
		<item>
		<title>[광우병] 2012 프리온 학회(암스테르담) 프로그램</title>
		<link>http://www.chsc.or.kr/?post_type=reference&#038;p=3324</link>
		<comments>http://www.chsc.or.kr/?post_type=reference&#038;p=3324#comments</comments>
		<pubDate>Tue, 15 May 2012 01:09:32 +0000</pubDate>
		<dc:creator>건강과대안</dc:creator>
				<category><![CDATA[광우병]]></category>
		<category><![CDATA[식품 · 의약품]]></category>
		<category><![CDATA[BSE]]></category>
		<category><![CDATA[Prion]]></category>
		<category><![CDATA[TSE]]></category>
		<category><![CDATA[암스테르담]]></category>
		<category><![CDATA[프리온]]></category>

		<guid isPermaLink="false">http://www.chsc.or.kr/?post_type=reference&#038;p=3324</guid>
		<description><![CDATA[http://prion2012.com/program/final-programWednesday May 9, 2012 Time Session Speakers Chair persons Room 12:00 &#8211; 20.00&#160; Registration open 13:00 &#8211; 18:00 Natural TSEs in Animals workshop Aula 18:00 &#8211; 20.00&#160; Welcome [...]]]></description>
				<content:encoded><![CDATA[<p><TABLE style="FONT-SIZE: 11px" border=0 cellSpacing=1 cellPadding=1 width=590><br />
<TBODY><br />
<TR><br />
<TD vAlign=top colSpan=5><br />
<H2><A href="http://prion2012.com/program/final-program">http://prion2012.com/program/final-program</A><BR><BR>Wednesday May 9, 2012</H2></TD></TR><br />
<TR><br />
<TD vAlign=top width=74>Time</TD><br />
<TD vAlign=top width=238>Session</TD><br />
<TD vAlign=top width=131>Speakers</TD><br />
<TD vAlign=top width=93>Chair persons</TD><br />
<TD vAlign=top width=52 align=right>Room</TD></TR><br />
<TR><br />
<TD bgColor=#ccc0da vAlign=top>12:00 &#8211; 20.00&nbsp;</TD><br />
<TD bgColor=#ccc0da vAlign=top colSpan=4>Registration open</TD></TR><br />
<TR><br />
<TD bgColor=#ccffcc vAlign=top>13:00 &#8211; 18:00</TD><br />
<TD bgColor=#ccffcc vAlign=top colSpan=3>Natural TSEs in Animals workshop</TD><br />
<TD bgColor=#ccffcc vAlign=top align=right>Aula</TD></TR><br />
<TR><br />
<TD bgColor=#ddd9c4 vAlign=top>18:00 &#8211; 20.00&nbsp;</TD><br />
<TD bgColor=#ddd9c4 vAlign=top colSpan=3>Welcome Reception&nbsp;</TD><br />
<TD bgColor=#ddd9c4 vAlign=top align=right>Foyer</TD></TR><br />
<TR><br />
<TD vAlign=top colSpan=5><br />
<H2><BR>Thursday May 10, 2012</H2></TD></TR><br />
<TR><br />
<TD vAlign=top width=74>Time</TD><br />
<TD vAlign=top width=238>Session</TD><br />
<TD vAlign=top width=131>Speakers</TD><br />
<TD vAlign=top width=93>Chair persons</TD><br />
<TD vAlign=top width=52 align=right>Room</TD></TR><br />
<TR><br />
<TD bgColor=#ccc0da vAlign=top>07:30 &#8211; 18.00&nbsp;</TD><br />
<TD bgColor=#ccc0da vAlign=top colSpan=4>Registration open</TD></TR><br />
<TR><br />
<TD bgColor=#ccffff vAlign=top>08:30 &#8211; 08:50&nbsp;</TD><br />
<TD bgColor=#ccffff vAlign=top>Opening Ceremony&nbsp;</TD><br />
<TD bgColor=#ccffff vAlign=top>Langeveld</TD><br />
<TD bgColor=#ccffff vAlign=top>&nbsp;</TD><br />
<TD bgColor=#ccffff vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ffff99 vAlign=top>08:50 &#8211; 09:40</TD><br />
<TD bgColor=#ffff99 vAlign=top>Plenary Lecture PLEN1: Prion propagation and its wider implications</TD><br />
<TD bgColor=#ffff99 vAlign=top>Collinge</TD><br />
<TD bgColor=#ffff99 vAlign=top>Langeveld / Deslys</TD><br />
<TD bgColor=#ffff99 vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ccffcc vAlign=top>09:40 &#8211; 10:10</TD><br />
<TD bgColor=#ccffcc vAlign=top>PrPSc structure &#038; nature of the agent</TD><br />
<TD bgColor=#ccffcc vAlign=top>Surewicz</TD><br />
<TD bgColor=#ccffcc vAlign=top>Langeveld / Deslys</TD><br />
<TD bgColor=#ccffcc vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ffcc99 vAlign=top>10:10 &#8211; 10:40</TD><br />
<TD bgColor=#ffcc99 vAlign=top>Break</TD><br />
<TD bgColor=#ffcc99 vAlign=top>&nbsp;</TD><br />
<TD bgColor=#ffcc99 vAlign=top>&nbsp;</TD><br />
<TD bgColor=#ffcc99 vAlign=top align=right>Foyer</TD></TR><br />
<TR><br />
<TD bgColor=#ccffcc vAlign=top>10:40 &#8211; 12:00</TD><br />
<TD bgColor=#ccffcc vAlign=top>PrPSc structure &#038; nature of the agent</TD><br />
<TD bgColor=#ccffcc vAlign=top>Somerville, Wille, Starck, Lührs</TD><br />
<TD bgColor=#ccffcc vAlign=top>Requena / Torres</TD><br />
<TD bgColor=#ccffcc vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ffcc99 vAlign=top>12:00 &#8211; 14:00</TD><br />
<TD bgColor=#ffcc99 vAlign=top>Lunch &#038; Poster Sessions&nbsp;</TD><br />
<TD bgColor=#ffcc99 vAlign=top>&nbsp;</TD><br />
<TD bgColor=#ffcc99 vAlign=top>&nbsp;</TD><br />
<TD bgColor=#ffcc99 vAlign=top align=right>Foyer</TD></TR><br />
<TR><br />
<TD bgColor=#ccffcc vAlign=top>14.00 &#8211; 16.00</TD><br />
<TD bgColor=#ccffcc vAlign=top>Transmission &#038; Strains</TD><br />
<TD bgColor=#ccffcc vAlign=top>Beringue, Van Keulen, Saa, David, Nonno, Kloehn</TD><br />
<TD bgColor=#ccffcc vAlign=top>Agrimi / Bossers</TD><br />
<TD bgColor=#ccffcc vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ffcc99 vAlign=top>16:00 &#8211; 16:30</TD><br />
<TD bgColor=#ffcc99 vAlign=top>Break</TD><br />
<TD bgColor=#ffcc99 vAlign=top>&nbsp;</TD><br />
<TD bgColor=#ffcc99 vAlign=top>&nbsp;</TD><br />
<TD bgColor=#ffcc99 vAlign=top align=right>Foyer</TD></TR><br />
<TR><br />
<TD bgColor=#ccffcc vAlign=top>16:30 &#8211; 17:25</TD><br />
<TD bgColor=#ccffcc vAlign=top>Pathogenesis &#038; Pathology&nbsp;</TD><br />
<TD bgColor=#ccffcc vAlign=top>Hoover, Mallucci, Godsave&nbsp;</TD><br />
<TD bgColor=#ccffcc vAlign=top>Jeffrey / De Koeijer</TD><br />
<TD bgColor=#ccffcc vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ccffcc vAlign=top>17:25 &#8211; 18:20</TD><br />
<TD bgColor=#ccffcc vAlign=top>Epidemiology &#038; risk analysis</TD><br />
<TD bgColor=#ccffcc vAlign=top>Van Duijn, Comer, Sala</TD><br />
<TD bgColor=#ccffcc vAlign=top>Jeffrey / De Koeijer</TD><br />
<TD bgColor=#ccffcc vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ddd9c4 vAlign=top>19:00</TD><br />
<TD bgColor=#ddd9c4 vAlign=top colSpan=3>Departure Social Event&nbsp;</TD><br />
<TD bgColor=#ddd9c4 vAlign=top align=right>VU</TD></TR><br />
<TR><br />
<TD bgColor=#ddd9c4 vAlign=top>19:30 &#8211; 24:00</TD><br />
<TD bgColor=#ddd9c4 vAlign=top colSpan=4>Social Event&nbsp;</TD></TR><br />
<TR><br />
<TD vAlign=top colSpan=5><br />
<H2><BR>Friday May 11, 2012</H2></TD></TR><br />
<TR><br />
<TD vAlign=top width=74>Time</TD><br />
<TD vAlign=top width=238>Session</TD><br />
<TD vAlign=top width=131>Speakers</TD><br />
<TD vAlign=top width=93>Chair persons</TD><br />
<TD vAlign=top width=52 align=right>Room</TD></TR><br />
<TR><br />
<TD bgColor=#ccc0da vAlign=top>08:00 &#8211; 18.00&nbsp;</TD><br />
<TD bgColor=#ccc0da vAlign=top colSpan=4>Registration open</TD></TR><br />
<TR><br />
<TD bgColor=#ffff99 vAlign=top>08:30 &#8211; 09:20</TD><br />
<TD bgColor=#ffff99 vAlign=top>Plenary Lecture PLEN2: Mechanisms of neurotoxicity in prion infections</TD><br />
<TD bgColor=#ffff99 vAlign=top>Aguzzi</TD><br />
<TD bgColor=#ffff99 vAlign=top>Rozemuller / Gambetti</TD><br />
<TD bgColor=#ffff99 vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ccffcc vAlign=top>09:20 &#8211; 10:30</TD><br />
<TD bgColor=#ccffcc vAlign=top>Protein folding diseases</TD><br />
<TD bgColor=#ccffcc vAlign=top>Dobson, Jeffrey, Shorter</TD><br />
<TD bgColor=#ccffcc vAlign=top>Rozemuller / Gambetti</TD><br />
<TD bgColor=#ccffcc vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ffcc99 vAlign=top>10:30 &#8211; 11:00</TD><br />
<TD bgColor=#ffcc99 vAlign=top>Break</TD><br />
<TD bgColor=#ffcc99 vAlign=top>&nbsp;</TD><br />
<TD bgColor=#ffcc99 vAlign=top>&nbsp;</TD><br />
<TD bgColor=#ffcc99 vAlign=top align=right>Foyer</TD></TR><br />
<TR><br />
<TD bgColor=#ccffcc vAlign=top>11:00 &#8211; 12:20</TD><br />
<TD bgColor=#ccffcc vAlign=top>Diagnosis &#038; therapeutics</TD><br />
<TD bgColor=#ccffcc vAlign=top>Caughey, Cashman, Schatzl, Nyström</TD><br />
<TD bgColor=#ccffcc vAlign=top>Sklaviadis / Pocchiari</TD><br />
<TD bgColor=#ccffcc vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ffcc99 vAlign=top>12:20 &#8211; 14:20</TD><br />
<TD bgColor=#ffcc99 vAlign=top>Lunch &#038; Poster Sessions&nbsp;</TD><br />
<TD bgColor=#ffcc99 vAlign=top>&nbsp;</TD><br />
<TD bgColor=#ffcc99 vAlign=top>&nbsp;</TD><br />
<TD bgColor=#ffcc99 vAlign=top align=right>Foyer</TD></TR><br />
<TR><br />
<TD bgColor=#ccffcc vAlign=top>14.20 &#8211; 15.25</TD><br />
<TD bgColor=#ccffcc vAlign=top>Susceptibility &#038; genetics</TD><br />
<TD bgColor=#ccffcc vAlign=top>Agrimi, Bossers, Stepanova</TD><br />
<TD bgColor=#ccffcc vAlign=top>Baron / Schatzl&nbsp;</TD><br />
<TD bgColor=#ccffcc vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ccffcc vAlign=top>15:25 &#8211; 16:25&nbsp;</TD><br />
<TD bgColor=#ccffcc vAlign=top>PrP biology &#038; function</TD><br />
<TD bgColor=#ccffcc vAlign=top>Tatzelt, Radfort, Westaway</TD><br />
<TD bgColor=#ccffcc vAlign=top>Baron / Schatzl&nbsp;</TD><br />
<TD bgColor=#ccffcc vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ffcc99 vAlign=top>16:25 &#8211; 16:55</TD><br />
<TD bgColor=#ffcc99 vAlign=top>Break</TD><br />
<TD bgColor=#ffcc99 vAlign=top>&nbsp;</TD><br />
<TD bgColor=#ffcc99 vAlign=top>&nbsp;</TD><br />
<TD bgColor=#ffcc99 vAlign=top align=right>Foyer</TD></TR><br />
<TR><br />
<TD bgColor=#ccffcc vAlign=top>16:55 &#8211; 17:20</TD><br />
<TD bgColor=#ccffcc vAlign=top>Patients and patient organisation(s)</TD><br />
<TD bgColor=#ccffcc vAlign=top>Solvyns, Kranitz&nbsp;</TD><br />
<TD bgColor=#ccffcc vAlign=top>Langeveld / Deslys</TD><br />
<TD bgColor=#ccffcc vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ccffcc vAlign=top>17:20 &#8211; 18:30</TD><br />
<TD bgColor=#ccffcc vAlign=top>Human prion diseases</TD><br />
<TD bgColor=#ccffcc vAlign=top>Gambetti, Rozemuller, Kovacs</TD><br />
<TD bgColor=#ccffcc vAlign=top>Budka / Veerhuis</TD><br />
<TD bgColor=#ccffcc vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ddd9c4 vAlign=top>18:30</TD><br />
<TD bgColor=#ddd9c4 vAlign=top colSpan=4>Free evening&nbsp;</TD></TR><br />
<TR><br />
<TD vAlign=top colSpan=5><br />
<H2><BR>Saturday May 12, 2012</H2></TD></TR><br />
<TR><br />
<TD vAlign=top width=74>Time</TD><br />
<TD vAlign=top width=238>Session</TD><br />
<TD vAlign=top width=131>Speakers</TD><br />
<TD vAlign=top width=93>Chair persons</TD><br />
<TD vAlign=top width=52 align=right>Room</TD></TR><br />
<TR><br />
<TD bgColor=#ccc0da vAlign=top>08:00 &#8211; 12:00&nbsp;</TD><br />
<TD bgColor=#ccc0da vAlign=top colSpan=4>Registration open</TD></TR><br />
<TR><br />
<TD bgColor=#ccffcc vAlign=top>08:30 &#8211; 09:20</TD><br />
<TD bgColor=#ccffcc vAlign=top>Blood safety, decontamination, environment</TD><br />
<TD bgColor=#ccffcc vAlign=top>Will, Simoneau, Comoy</TD><br />
<TD bgColor=#ccffcc vAlign=top>Brown / Deslys</TD><br />
<TD bgColor=#ccffcc vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ccffff vAlign=top>09:20 &#8211; 10:00</TD><br />
<TD bgColor=#ccffff vAlign=top>Poster Award Winners Ceremony</TD><br />
<TD bgColor=#ccffff vAlign=top>To be announced on site</TD><br />
<TD bgColor=#ccffff vAlign=top>Poster Jury&nbsp;</TD><br />
<TD bgColor=#ccffff vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ffcc99 vAlign=top>10:00 &#8211; 10:30</TD><br />
<TD bgColor=#ffcc99 vAlign=top>Break</TD><br />
<TD bgColor=#ffcc99 vAlign=top>&nbsp;</TD><br />
<TD bgColor=#ffcc99 vAlign=top>&nbsp;</TD><br />
<TD bgColor=#ffcc99 vAlign=top align=right>Foyer</TD></TR><br />
<TR><br />
<TD bgColor=#ccffcc vAlign=top>10:30 &#8211; 11:50</TD><br />
<TD bgColor=#ccffcc vAlign=top>Hot Topics&nbsp;</TD><br />
<TD bgColor=#ccffcc vAlign=top>Van Nostrand, Baskakov, Castilla, Baron, Zou<BR></TD><br />
<TD bgColor=#ccffcc vAlign=top>Manson / Tagliavini&nbsp;</TD><br />
<TD bgColor=#ccffcc vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ccffff vAlign=top>11:50 &#8211; 12:00</TD><br />
<TD bgColor=#ccffff vAlign=top>Closing ceremony</TD><br />
<TD bgColor=#ccffff vAlign=top>Langeveld</TD><br />
<TD bgColor=#ccffff vAlign=top>&nbsp;</TD><br />
<TD bgColor=#ccffff vAlign=top align=right>Aula&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ddd9c4 vAlign=top>12:00</TD><br />
<TD bgColor=#ddd9c4 vAlign=top colSpan=4>End conference / next conference / departure</TD></TR></TBODY></TABLE><br />
<P><SPAN style="FONT-SIZE: 10px"></SPAN></P><br />
<P>&nbsp;</P><br />
<H1>Sessions</H1><br />
<TABLE style="FONT-SIZE: 11px" border=0 cellSpacing=1 cellPadding=1 width=590><br />
<TBODY><br />
<TR><br />
<TD vAlign=top colSpan=4><br />
<H2>Thursday May 10, 2012&nbsp; 09h40 &#8211; 18h20</H2></TD></TR><br />
<TR><br />
<TD vAlign=top colSpan=3>Session: PrPSc structure &#038; nature of the agent&nbsp;&nbsp;</TD><br />
<TD vAlign=top width=118>Chair persons: Langeveld, Deslys, Requena, Torres</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top width=42>OR-01</TD><br />
<TD bgColor=#ebf1de vAlign=top width=75>09:40 &#8211; 10:10</TD><br />
<TD bgColor=#ebf1de vAlign=top width=340>THE CHALLENGE OF STRUCTURAL UNDERSTANDING OF PRION PROTEIN CONVERSION AND PRION PROPAGATION</TD><br />
<TD bgColor=#ebf1de vAlign=top>Surewicz</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-02</TD><br />
<TD bgColor=#ebf1de vAlign=top>10:40 &#8211; 11:05</TD><br />
<TD bgColor=#ebf1de vAlign=top>INTRINSIC STRUCTURAL AND FUNCTIONAL PROPERTIES OF EXPERIMENTAL TSE STRAINS</TD><br />
<TD bgColor=#ebf1de vAlign=top>Somerville</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-03</TD><br />
<TD bgColor=#ebf1de vAlign=top>11:05 &#8211; 11:25</TD><br />
<TD bgColor=#ebf1de vAlign=top>A COMPACT, FOUR-STRANDED BETA-SHEET CORE IS FOUND IN PRIONS FROM ALL NATURAL PRION ISOLATES AND SYNTHETIC PRION STRAINS ANALYZED</TD><br />
<TD bgColor=#ebf1de vAlign=top>Wille</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-04</TD><br />
<TD bgColor=#ebf1de vAlign=top>11:25 &#8211; 11:40</TD><br />
<TD bgColor=#ebf1de vAlign=top>STRUCTURE AND DYNAMICS OF A TOXIC SYRIAN HAMSTER PRION PROTEIN BETA-INTERMEDIATE</TD><br />
<TD bgColor=#ebf1de vAlign=top>Starck&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-05</TD><br />
<TD bgColor=#ebf1de vAlign=top>11:40 &#8211; 12:00</TD><br />
<TD bgColor=#ebf1de vAlign=top>CONFORMATION SELECTIVE PRION AMPLIFICATION USING SPECIFIC SHEAR FIELDS</TD><br />
<TD bgColor=#ebf1de vAlign=top>Lührs</TD></TR><br />
<TR><br />
<TD vAlign=top colSpan=3>Session: Transmission &#038; Strains&nbsp;</TD><br />
<TD vAlign=top>Chair persons: <BR>Agrimi, Bossers</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-06</TD><br />
<TD bgColor=#ebf1de vAlign=top>14:00 &#8211; 14:30</TD><br />
<TD bgColor=#ebf1de vAlign=top>PRION DIVERSITY AND EVOLUTION: WHAT ANIMAL STRAIN TYPING TELLS US&nbsp;</TD><br />
<TD bgColor=#ebf1de vAlign=top>Beringue</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-07</TD><br />
<TD bgColor=#ebf1de vAlign=top>14:30 &#8211; 14:55</TD><br />
<TD bgColor=#ebf1de vAlign=top>PRPSC PROFILES IN TSE STRAINTYPING&nbsp;</TD><br />
<TD bgColor=#ebf1de vAlign=top>Van Keulen</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-08</TD><br />
<TD bgColor=#ebf1de vAlign=top>14:55 &#8211; 15:10</TD><br />
<TD bgColor=#ebf1de vAlign=top>STRAIN–SPECIFIC ROLE OF RNAS IN PRION REPLICATION</TD><br />
<TD bgColor=#ebf1de vAlign=top>Saa</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-09</TD><br />
<TD bgColor=#ebf1de vAlign=top>15:10 &#8211; 15:25</TD><br />
<TD bgColor=#ebf1de vAlign=top>CANINE SPONGIFORM ENCEPHALOPATHY: A NEW FORM OF ANIMAL PRION DISEASE</TD><br />
<TD bgColor=#ebf1de vAlign=top>David</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-10</TD><br />
<TD bgColor=#ebf1de vAlign=top>15:25 &#8211; 15:40</TD><br />
<TD bgColor=#ebf1de vAlign=top>VARIABLY PROTEASE-SENSITIVE PRIONOPATHY IS TRANSMISSIBLE IN BANK VOLES</TD><br />
<TD bgColor=#ebf1de vAlign=top>Nonno</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-11</TD><br />
<TD bgColor=#ebf1de vAlign=top>15:40 &#8211; 16:00</TD><br />
<TD bgColor=#ebf1de vAlign=top>PLASMACYTOID DENDRITIC CELLS SEQUESTER HIGH PRION TITRES AT EARLY STAGES OF PRION INFECTION</TD><br />
<TD bgColor=#ebf1de vAlign=top>Kloehn&nbsp;</TD></TR><br />
<TR><br />
<TD vAlign=top colSpan=3>Session: Pathogenesis &#038; Pathology&nbsp;</TD><br />
<TD vAlign=top>Chair persons: <BR>Jeffrey, De Koeijer</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-12</TD><br />
<TD bgColor=#ebf1de vAlign=top>16:30 &#8211; 16:55</TD><br />
<TD bgColor=#ebf1de vAlign=top>PRION DIVERSITY AND EVOLUTION: WHAT ANIMAL STRAIN TYPING TELLS US&nbsp;</TD><br />
<TD bgColor=#ebf1de vAlign=top>Hoover</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-13</TD><br />
<TD bgColor=#ebf1de vAlign=top>16:55 &#8211; 17:10</TD><br />
<TD bgColor=#ebf1de vAlign=top>SUSTAINED TRANSLATIONAL REPRESSION BY EIF2alpha-P MEDIATES PRION NEURODEGENERATION</TD><br />
<TD bgColor=#ebf1de vAlign=top>Malluci&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-14</TD><br />
<TD bgColor=#ebf1de vAlign=top>17:10 &#8211; 17:25</TD><br />
<TD bgColor=#ebf1de vAlign=top>EARLY PLASMA MEMBRANE ACCUMULATIONS OF NASCENT PRIONS IN HIPPOCAMPUS; POSSIBLE SITES OF REPLICATION, CELL-TO CELL TRANSFER AND PATHOLOGY</TD><br />
<TD bgColor=#ebf1de vAlign=top>Godsave</TD></TR><br />
<TR><br />
<TD vAlign=top colSpan=3>Session: Epidemiology &#038; risk analysis</TD><br />
<TD vAlign=top>Chair persons: <BR>Jeffrey, De Koeijer&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-15</TD><br />
<TD bgColor=#ebf1de vAlign=top>17:25 &#8211; 17:50</TD><br />
<TD bgColor=#ebf1de vAlign=top>ADVANCES IN THE GENETIC EPIDEMIOLOGY OF CREUTZFELDT-JAKOB DISEASE AND RELATED DISEASES&nbsp;</TD><br />
<TD bgColor=#ebf1de vAlign=top>Van Duijn&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-16</TD><br />
<TD bgColor=#ebf1de vAlign=top>17:50 &#8211; 18:05</TD><br />
<TD bgColor=#ebf1de vAlign=top>A COST EFFECTIVENESS STUDY OF THE USE OF ANTE-MORTEM TSE TESTS ON CATTLE IN THE UK</TD><br />
<TD bgColor=#ebf1de vAlign=top>Comer</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-17</TD><br />
<TD bgColor=#ebf1de vAlign=top>18:05 &#8211; 18:20</TD><br />
<TD bgColor=#ebf1de vAlign=top>OLD CATTLE AND THE RISK OF ATYPICAL BOVINE SPONGIFORM ENCEPHALOPATHY</TD><br />
<TD bgColor=#ebf1de vAlign=top>Sala&nbsp;</TD></TR></TBODY></TABLE><br />
<P><SPAN style="FONT-SIZE: 10px"></SPAN></P><br />
<P>&nbsp;</P><br />
<TABLE style="FONT-SIZE: 11px" border=0 cellSpacing=1 cellPadding=1 width=590><br />
<TBODY><br />
<TR><br />
<TD vAlign=top colSpan=4><br />
<H2>Friday May 11, 2012&nbsp; 09h20 &#8211; 18h30</H2></TD></TR><br />
<TR><br />
<TD vAlign=top colSpan=3>Session: Protein folding diseases</TD><br />
<TD vAlign=top width=118>Chair persons: Rozemuller, Gambetti&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top width=42>OR-18</TD><br />
<TD bgColor=#ebf1de vAlign=top width=75>09:20 &#8211; 09:50</TD><br />
<TD bgColor=#ebf1de vAlign=top width=340>THE NATURE AND SIGNIFICANCE OF PROTEIN AGGREGATION PHENOMENA</TD><br />
<TD bgColor=#ebf1de vAlign=top>Dobson</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-19</TD><br />
<TD bgColor=#ebf1de vAlign=top>09:50 &#8211; 10:15</TD><br />
<TD bgColor=#ebf1de vAlign=top>SYNTHETIC PRP RELATED DISORDERS AND NATURAL TSES SHARE DISEASE ASSOCIATED PRP MEMBRANCE ACCUMULATION&nbsp;</TD><br />
<TD bgColor=#ebf1de vAlign=top>Jeffrey</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-20</TD><br />
<TD bgColor=#ebf1de vAlign=top>10:15 &#8211; 10:30</TD><br />
<TD bgColor=#ebf1de vAlign=top>RNA-BINDING PROTEINS WITH PRION-LIKE DOMAINS IN ALS AND BEYOND</TD><br />
<TD bgColor=#ebf1de vAlign=top>Shorter</TD></TR><br />
<TR><br />
<TD vAlign=top colSpan=3>Session: Diagnosis &#038; therapeutics</TD><br />
<TD vAlign=top>Chair persons: Kretzschmar, Pocchiari</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-21</TD><br />
<TD bgColor=#ebf1de vAlign=top>11:00 &#8211; 11:30</TD><br />
<TD bgColor=#ebf1de vAlign=top>PRION-SEEDED CONVERSION OF RECOMBINANT PRP: IMPLICATIONS FOR PRION BIOLOGY AND DIAGNOSTICS</TD><br />
<TD bgColor=#ebf1de vAlign=top>Caughey</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-22</TD><br />
<TD bgColor=#ebf1de vAlign=top>11:30 &#8211; 11:50</TD><br />
<TD bgColor=#ebf1de vAlign=top>PROPAGATED MISFOLDING OF SOD1 IN ALS</TD><br />
<TD bgColor=#ebf1de vAlign=top>Cashman</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-23</TD><br />
<TD bgColor=#ebf1de vAlign=top>11:50 &#8211; 12:05</TD><br />
<TD bgColor=#ebf1de vAlign=top>ELUCIDATING THE CELLULAR MECHANISMS OF PRION PROPAGATION AND CLEARANCE FOR DEVISING NEW TARGETS FOR INTERVENTION</TD><br />
<TD bgColor=#ebf1de vAlign=top>Schatzl&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-24</TD><br />
<TD bgColor=#ebf1de vAlign=top>12:05 &#8211; 12:20</TD><br />
<TD bgColor=#ebf1de vAlign=top>MONITORING AMYLOID FORMATION AND MATURATION IN VITRO AND IN VIVO USING LCO FLUORESCENCE</TD><br />
<TD bgColor=#ebf1de vAlign=top>Nyström</TD></TR><br />
<TR><br />
<TD vAlign=top colSpan=3>Session: Susceptibility &#038; genetics</TD><br />
<TD vAlign=top>Chair persons: <BR>Baron, Schatzl&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-25</TD><br />
<TD bgColor=#ebf1de vAlign=top>14:20 &#8211; 14:45</TD><br />
<TD bgColor=#ebf1de vAlign=top>PRNP AND SUSCEPTIBILITY TO PRION DISEASES: FROM RESISTANCE TO SPONTANEOUS DISEASE</TD><br />
<TD bgColor=#ebf1de vAlign=top>Agrimi&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-26</TD><br />
<TD bgColor=#ebf1de vAlign=top>14:45 &#8211; 15:10</TD><br />
<TD bgColor=#ebf1de vAlign=top>MOLECULAR ASSESSMENT OF RUMINANT SUSCEPTIBILITY FOR VARIOUS TSE SOURCES</TD><br />
<TD bgColor=#ebf1de vAlign=top>Bossers</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-27</TD><br />
<TD bgColor=#ebf1de vAlign=top>15:10 &#8211; 15:25</TD><br />
<TD bgColor=#ebf1de vAlign=top>COMPARATIVE ANALYSIS OF PRION PROTEINS FOR EVOLUTIONARILY DIVERSE VERTEBRAE SPECIES, POLYMORPHIC VARIANTS AND MUTANTS: STRUCTURE AND ESSENTIAL DYNAMICS</TD><br />
<TD bgColor=#ebf1de vAlign=top>Stepanova</TD></TR><br />
<TR><br />
<TD vAlign=top colSpan=3>Session: PrP biology &#038; function</TD><br />
<TD vAlign=top>Chair persons: <BR>Baron, Schaltz</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-28</TD><br />
<TD bgColor=#ebf1de vAlign=top>15:25 &#8211; 15:50</TD><br />
<TD bgColor=#ebf1de vAlign=top>THE CELLULAR PRION PROTEIN MEDIATES NEUROTOXIC SIGNALING OF SCRAPIE PRIONS AND AB</TD><br />
<TD bgColor=#ebf1de vAlign=top>Tatzelt</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-29</TD><br />
<TD bgColor=#ebf1de vAlign=top>15:50 &#8211; 16:05</TD><br />
<TD bgColor=#ebf1de vAlign=top>THE ROLE OF PRP IN SYNAPTIC FUNCTION AND REPAIR: IMPLICATIONS FOR TREATMENT OF PRION AND ALZHEIMER’S DISEASES</TD><br />
<TD bgColor=#ebf1de vAlign=top>Radfort</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-30</TD><br />
<TD bgColor=#ebf1de vAlign=top>16:05 &#8211; 16:25</TD><br />
<TD bgColor=#ebf1de vAlign=top>PROPERTIES OF GEOMETRY-LOCKED PRPS AND SHADOO PROTEIN IN HEALTH AND DISEASE&nbsp;</TD><br />
<TD bgColor=#ebf1de vAlign=top>Westaway</TD></TR><br />
<TR><br />
<TD vAlign=top colSpan=3>Session: Human prion diseases</TD><br />
<TD vAlign=top>Chair persons: <BR>Budka, Veerhuis</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-31</TD><br />
<TD bgColor=#ebf1de vAlign=top>17:20 &#8211; 17:50</TD><br />
<TD bgColor=#ebf1de vAlign=top>PRION STRAINS IN HUMAN PRION DISEASES: VARIABLY PROTEASE-SENSITIVE PRIONOPATHTY COMPARED WITH OTHER</TD><br />
<TD bgColor=#ebf1de vAlign=top>Gambetti</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-32</TD><br />
<TD bgColor=#ebf1de vAlign=top>17:50 &#8211; 18:15</TD><br />
<TD bgColor=#ebf1de vAlign=top>HUMAN PRION DISEASES IN THE NETHERLANDS (1998-2009): CLINICAL, GENETIC AND MOLECULAR ASPECTS&nbsp;</TD><br />
<TD bgColor=#ebf1de vAlign=top>Rozemuller</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-33</TD><br />
<TD bgColor=#ebf1de vAlign=top>18:15 &#8211; 18:30</TD><br />
<TD bgColor=#ebf1de vAlign=top>THALAMIC DEGENERATION CLINICALLY PRESENTING AS CJD: MORE FREQUENT THAN ASSUMED?</TD><br />
<TD bgColor=#ebf1de vAlign=top>Kovacs</TD></TR></TBODY></TABLE><br />
<P><SPAN style="FONT-SIZE: 10px"></SPAN></P><br />
<P>&nbsp;</P><br />
<TABLE style="FONT-SIZE: 11px" border=0 cellSpacing=1 cellPadding=1 width=590><br />
<TBODY><br />
<TR><br />
<TD vAlign=top colSpan=4><br />
<H2>Saturday May 12, 2012&nbsp; 08h30 &#8211; 12h00</H2></TD></TR><br />
<TR><br />
<TD vAlign=top colSpan=3>Session: Blood safety, decontamination, environment</TD><br />
<TD vAlign=top width=118>Chair persons: <BR>Brown, Deslys</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top width=42>OR-34</TD><br />
<TD bgColor=#ebf1de vAlign=top width=75>08:30 &#8211; 08:50</TD><br />
<TD bgColor=#ebf1de vAlign=top width=340>AN UPDATE OF TRANSFUSION TRANSMISSION OF VARIANT CREUTZFELDT-JAKOB DISEASE (VCJD)</TD><br />
<TD bgColor=#ebf1de vAlign=top>Will&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-35</TD><br />
<TD bgColor=#ebf1de vAlign=top>08:50 &#8211; 09:05</TD><br />
<TD bgColor=#ebf1de vAlign=top>EFFICACY OF ETHANOL PRECIPITATION (TI+III + TII) AND NANOFILTRATION IN REMOVAL OF A HIGH SPEED PURIFIED NON SEDIMENTABLE PRION SPIKE</TD><br />
<TD bgColor=#ebf1de vAlign=top>Simoneau&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-36</TD><br />
<TD bgColor=#ebf1de vAlign=top>09:05 &#8211; 09:20</TD><br />
<TD bgColor=#ebf1de vAlign=top>A NEW NEUROLOGICAL DISEASE IN PRIMATES INOCULATED WITH PRION-INFECTED BLOOD OR BLOOD COMPONENTS</TD><br />
<TD bgColor=#ebf1de vAlign=top>Comoy</TD></TR><br />
<TR><br />
<TD vAlign=top colSpan=2>Session: Hot topics&nbsp;&nbsp;</TD><br />
<TD vAlign=top>&nbsp;</TD><br />
<TD vAlign=top>Chair persons: <BR>Manson, Tagliavini</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-37</TD><br />
<TD bgColor=#ebf1de vAlign=top>10:30 &#8211; 10:50</TD><br />
<TD bgColor=#ebf1de vAlign=top>CONDITIONAL CROSS SEEDING OF NORMAL AND VASCULOTROPIC MUTANT AMYLOID B-PROTEIN IN TRANSGENIC MICE</TD><br />
<TD bgColor=#ebf1de vAlign=top>Van Nostrand</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-38</TD><br />
<TD bgColor=#ebf1de vAlign=top>10:50 &#8211; 11:05</TD><br />
<TD bgColor=#ebf1de vAlign=top>GENESIS OF MAMMALIAN PRIONS</TD><br />
<TD bgColor=#ebf1de vAlign=top>Baskakov</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-39</TD><br />
<TD bgColor=#ebf1de vAlign=top>11:05 &#8211; 11:20</TD><br />
<TD bgColor=#ebf1de vAlign=top>HIGHLY INFECTIOUS RECOMBINANT PRIONS: A NEW CHALLENGE FOR UNDERSTANDING HOW PRIONS WORK</TD><br />
<TD bgColor=#ebf1de vAlign=top>Castilla</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-40</TD><br />
<TD bgColor=#ebf1de vAlign=top>11:20 &#8211; 11:35</TD><br />
<TD bgColor=#ebf1de vAlign=top>PRION-LIKE ACCELERATION OF A SYNUCLEINOPATHY IN A TRANSGENIC MOUSE MODEL</TD><br />
<TD bgColor=#ebf1de vAlign=top>Baron&nbsp;</TD></TR><br />
<TR><br />
<TD bgColor=#ebf1de vAlign=top>OR-41</TD><br />
<TD bgColor=#ebf1de vAlign=top>11:35 &#8211; 11:50</TD><br />
<TD bgColor=#ebf1de vAlign=top>RIONS LACKING GLYCOSYLATED PRP AT THE FIRST N-GLYCOSYLATION SITE IN BOTH VARIABLY PROTEASE-SENSITIVE PRIONOPATHY AND A FAMILIAL PRION DISEASE <BR></TD></TR></TBODY></TABLE></p>
]]></content:encoded>
			<wfw:commentRss>http://www.chsc.or.kr/?post_type=reference&#038;p=3324/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>[광우병] 프리온 단백질 전염, 양(Abundance)이 아니라 크기(Size)가 문제</title>
		<link>http://www.chsc.or.kr/?post_type=reference&#038;p=2347</link>
		<comments>http://www.chsc.or.kr/?post_type=reference&#038;p=2347#comments</comments>
		<pubDate>Tue, 02 Nov 2010 19:07:31 +0000</pubDate>
		<dc:creator>건강과대안</dc:creator>
				<category><![CDATA[광우병]]></category>
		<category><![CDATA[식품 · 의약품]]></category>
		<category><![CDATA[Abundance]]></category>
		<category><![CDATA[aggregates]]></category>
		<category><![CDATA[BSE]]></category>
		<category><![CDATA[chaperones]]></category>
		<category><![CDATA[misfold]]></category>
		<category><![CDATA[Prion]]></category>
		<category><![CDATA[Size]]></category>
		<category><![CDATA[vCJD]]></category>
		<category><![CDATA[인간광우병]]></category>

		<guid isPermaLink="false">http://www.chsc.or.kr/?post_type=reference&#038;p=2347</guid>
		<description><![CDATA[브라운대학의 연구팀이 광우병, 인간광우병 등 프리온 질병의 전염에서 중요한 역할을 하는 것이 프리온 단백질이 얼마나 풍부하게 있느냐가 아니라 단백질 결집체의 크기라는 연구결과를 최근 발표했다는 소식입니다. 효모의 프리온 단백질을 [...]]]></description>
				<content:encoded><![CDATA[<p>브라운대학의 연구팀이 광우병, 인간광우병 등 프리온 질병의 전염에서 중요한 역할을 하는 것이 프리온 단백질이 얼마나 풍부하게 있느냐가 아니라 단백질 결집체의 크기라는 연구결과를 최근 발표했다는 소식입니다. <BR><BR>효모의 프리온 단백질을 이용한 연구이지만&#8230; 앞으로 CJD, 알츠하이머, 파킨슨병 등의 질병 연구와 치료에 기초가 될 수 있을 것으로 추정됩니다.<BR><BR>세포 내에서 비정상 프리온 단백질이 misfold될 때&nbsp; aggregates를 형성하는데, 샤프런( chaperones) 같은 단백질은 aggregates를 파괴하려고 합니다.&nbsp; 단백질이 집합체를 형성하느냐,아니면 집합체를 파괴하느냐의 비율은&nbsp;프리온 단백질의 형태(shape) 또는&nbsp;구성(conformation)에 따라 결정된다고 합니다.<BR><BR>====================================<BR><BR>Size Of Protein Aggregates, Not Abundance, Drives Spread Of Prion-Based Disease<BR><BR><SPAN><B id=yui_3_1_1_1_1288691645453332 _yuid="yui_3_1_1_1_1288691645453327">출처 : Medical News Today</B></SPAN>&nbsp; Article Date: 01 Nov 2010 &#8211; 0:00 PDT<BR><A href="http://www.medicalnewstoday.com/articles/206190.php">http://www.medicalnewstoday.com/articles/206190.php</A><BR><BR>Mad Cow disease and its human variant <A title="What Is Creutzfeldt-Jakob Disease (CJD)? What Is Mad Cow Disease?" href="/articles/185884.php">Creutzfeldt-Jakob disease</A>, which are incurable and fatal, have been on a welcome hiatus from the news for years, but because mammals remain as vulnerable as ever to infectious diseases caused by enigmatic proteins called prions, scientists have taken no respite of their own. In the Oct. 29 edition of the journal Science, researchers at Brown University report a key new insight into how prion proteins &#8211; the infectious agents &#8211; become transmissible: In yeast at least, it is the size of prion complexes, not their number, that determines their efficiency in spreading. <BR><BR>&#8220;The dogma in the field was that the misfolding of the protein is sufficient to cause disease, and the clinical course of the infection depended on the amplification of the misfolded protein,&#8221; said Tricia Serio, associate professor of molecular biology, cell biology and biochemistry. &#8220;But over the years in mammals it has become clear that the abundance of misfolded protein is not a good predictor of disease progression. The question is, What else has to happen for you to get the clinical pathology?&#8221; <BR><BR>Cells make prion proteins naturally, although biologists do not understand what their normal role is in mammals. When those proteins misfold in cells, they assemble into structures called aggregates, but other proteins, known as chaperones, attempt to break down the aggregates. The rates at which this assembly and disassembly occurs are determined by the shape or conformation that the prion protein has adopted. <BR><BR>&#8220;Different conformations of the same prion protein can dramatically alter the spread of pathology and the incubation time of prion diseases,&#8221; Serio said. &#8220;We wanted to learn how.&#8221; <BR><BR>By combining experiments in yeast cells with mathematical models, the Brown team found that what affects a prions&#8217; ability to transmit from cell to cell is the size of the structures into which they assemble, Serio said. If the aggregates become too large, they lose their transmissibility among cells. Prion aggregates that remain small are transmitted with greater efficiency. <BR><BR>&#8220;In this paper we changed the transmissibility just by shifting the size,&#8221; Serio said. &#8220;We could change it in either direction.&#8221; <BR><BR>The proof was plain to see. Postdoctoral researcher Aaron Derdowski monitored differently sized prion aggregates as they moved among cells under the microscope and could see that smaller ones fared better than larger ones. He also kept track of the spread of different prion structures through a genetic analysis of affected cell populations. <BR><BR>In concert with the experimental work, Suzanne Sindi, a postdoctoral researcher with a joint appointment in molecular biology, cell biology and biochemistry and the Center for Computational Molecular Biology, modeled how cells make and spread prion aggregates, providing a novel simulation of the process that she ran on a computing cluster in the Center for Computation and Visualization at Brown. The model that best replicated experimental observations was the one in which aggregate size, rather than abundance, was the key factor. <BR><BR>Implications for disease <BR><BR>Serio says the insights the team has gained in yeast may better explain what others have observed in mammals as well. <BR><BR>&#8220;Previously it was not clear why you would have those outcomes,&#8221; she said. <BR><BR>Ultimately the findings could inform future strategies for developing a treatment for prion infection. If researchers unaware of the importance of aggregate size developed a therapy to hinder prion aggregate formation, they might inadvertently make things worse by producing smaller aggregates, Serio said. <BR><BR>&#8220;A more effective strategy might be to control the size of the aggregates,&#8221; she said, &#8220;rather than their presence or absence.&#8221; <BR><BR>The findings may also relate to other neurodegenerative diseases that depend on misfolding proteins, such as <A title="What Is Alzheimer's Disease? What Causes Alzheimer's Disease?" href="/articles/159442.php">Alzheimer&#8217;s disease</A> or <A title="What is Parkinson's Disease?" href="/info/parkinsons-disease/">Parkinson&#8217;s disease</A>, Serio said. <BR><BR>Other authors on the paper include graduate students Courtney Klaips and Susanne DiSalvo. The National Institutes of Health funded the work. <BR><BR>Source:<BR>David Orenstein<BR>Brown University <A name=ratethis></A><BR clear=all></p>
]]></content:encoded>
			<wfw:commentRss>http://www.chsc.or.kr/?post_type=reference&#038;p=2347/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>[광우병] 국립수의과학검역원 프리온 관련 연구용역 발주현황</title>
		<link>http://www.chsc.or.kr/?post_type=reference&#038;p=2296</link>
		<comments>http://www.chsc.or.kr/?post_type=reference&#038;p=2296#comments</comments>
		<pubDate>Thu, 16 Sep 2010 18:37:12 +0000</pubDate>
		<dc:creator>건강과대안</dc:creator>
				<category><![CDATA[광우병]]></category>
		<category><![CDATA[식품 · 의약품]]></category>
		<category><![CDATA[Prion]]></category>
		<category><![CDATA[국립수의과학검역원]]></category>
		<category><![CDATA[미국산 쇠고기 수입]]></category>
		<category><![CDATA[연구용역]]></category>
		<category><![CDATA[캐나다산 쇠고기 수입]]></category>
		<category><![CDATA[프리온]]></category>

		<guid isPermaLink="false">http://www.chsc.or.kr/?post_type=reference&#038;p=2296</guid>
		<description><![CDATA[&#160; 1. ‘06년 이후 프리온 연구관련 외부 용역 현황 - 용역수행자, 소속, 연구 결과 □ ‘06년 이후 프리온 외부용역연구 현황 과 제 명 연구 기간 용역수행자 및 소속 [...]]]></description>
				<content:encoded><![CDATA[<p><P style="MARGIN-TOP: 10pt" class=바탕글>&nbsp;</P><br />
<TABLE style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; BORDER-COLLAPSE: collapse; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid"><br />
<TBODY><br />
<TR><br />
<TD style="BORDER-BOTTOM: #000000 1.7pt solid; BORDER-LEFT: #000000 1.7pt solid; WIDTH: 457.76pt; HEIGHT: 66.08pt; BORDER-TOP: #000000 1.7pt solid; BORDER-RIGHT: #000000 1.7pt solid" vAlign=center><br />
<P style="LINE-HEIGHT: 180%; LAYOUT-GRID-MODE: char; MARGIN-RIGHT: 6pt" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 16pt; FONT-WEIGHT: bold; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>1. ‘06년 이후 프리온 연구관련 외부 용역 현황</SPAN></P><br />
<P style="LINE-HEIGHT: 180%; LAYOUT-GRID-MODE: char; MARGIN-RIGHT: 6pt" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 16pt; FONT-WEIGHT: bold; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>- 용역수행자, 소속, 연구 결과</SPAN></P></TD></TR></TBODY></TABLE><br />
<P></P><br />
<P style="TEXT-ALIGN: center" class=바탕글><br />
<P class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 16pt; FONT-WEIGHT: bold; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">□ ‘06년 이후 프리온 외부용역연구 현황</SPAN></P><br />
<P class=바탕글></P><br />
<TABLE style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; BORDER-COLLAPSE: collapse; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid"><br />
<TBODY><br />
<TR><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 106.6pt; HEIGHT: 45.11pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 13pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">과 제 명</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 38.68pt; HEIGHT: 45.11pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 13pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">연구</SPAN></P><br />
<P style="TEXT-ALIGN: center" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 13pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">기간</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 78.41pt; HEIGHT: 45.11pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 13pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">용역수행자 및 소속</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 233.23pt; HEIGHT: 45.11pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 13pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">연 구 결 과 요약</SPAN></P></TD></TR><br />
<TR><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 106.6pt; HEIGHT: 176.69pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">프리온질병 감수성 모델 개발</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 38.68pt; HEIGHT: 176.69pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>2007, 2010</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 78.41pt; HEIGHT: 176.69pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">박 승 용</SPAN></P><br />
<P style="TEXT-ALIGN: center" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>(건국대)</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 233.23pt; HEIGHT: 176.69pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>◦ 소, 사슴 및 재래산양의 프리온 단백질</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US> 유전자 분석</SPAN></P><br />
<P class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>◦ 사슴(엘크, 꽃사슴)의 프리온 단백질을</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US> 발현하는 마우스 모델 확립</SPAN></P></TD></TR><br />
<TR><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 106.6pt; HEIGHT: 148.63pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">국내사육 소의 BSE 감수성 인자</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US> 분석 연구</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 38.68pt; HEIGHT: 148.63pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>2007</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 78.41pt; HEIGHT: 148.63pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">신 형 두</SPAN></P><br />
<P style="TEXT-ALIGN: center" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>(주)엑스엔피)</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 233.23pt; HEIGHT: 148.63pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US></SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">◦ 국내 사육 한우 및 젖소의 BSE 감수성</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US> 인자 구명</SPAN></P></TD></TR></TBODY></TABLE><br />
<P></P><br />
<P class=바탕글><br />
<P class=바탕글><br />
<P class=바탕글><br />
<P class=바탕글><br />
<P class=바탕글></P><br />
<TABLE style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; BORDER-COLLAPSE: collapse; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid"><br />
<TBODY><br />
<TR><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 450.87pt; HEIGHT: 34.63pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 14pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">작성자: 국립수의과학검역원 기획조정과 이명헌연구관(T: 031-467-1951)</SPAN></P></TD></TR></TBODY></TABLE><br />
<P></P><br />
<P class=바탕글><SPAN style="FONT-FAMILY: 한양중고딕; FONT-SIZE: 15pt; mso-fareast-font-family: 한양중고딕; mso-hansi-font-family: 한양중고딕" lang=EN-US></SPAN><U style="text-underline: #000000 double"><SPAN style="FONT-FAMILY: 한양중고딕; FONT-SIZE: 24pt; FONT-WEIGHT: bold; mso-fareast-font-family: 한양중고딕; mso-hansi-font-family: 한양중고딕" lang=EN-US>BSE 연구 현황</SPAN></U></P><br />
<P style="TEXT-ALIGN: right" class=바탕글></P><br />
<TABLE style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; BORDER-COLLAPSE: collapse; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid"><br />
<TBODY><br />
<TR><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 1.7pt solid; WIDTH: 37.96pt; HEIGHT: 20.48pt; BORDER-TOP: #000000 1.7pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">번호</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 244.55pt; HEIGHT: 20.48pt; BORDER-TOP: #000000 1.7pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">연구과제명</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 72.75pt; HEIGHT: 20.48pt; BORDER-TOP: #000000 1.7pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">연구기간</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 54.77pt; HEIGHT: 20.48pt; BORDER-TOP: #000000 1.7pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">연구예산</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 317.96pt; HEIGHT: 20.48pt; BORDER-TOP: #000000 1.7pt solid; BORDER-RIGHT: #000000 1.7pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 12pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">연구결과</SPAN></P></TD></TR><br />
<TR><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 1.7pt solid; WIDTH: 37.96pt; HEIGHT: 44.62pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>1</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 244.55pt; HEIGHT: 44.62pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">전염성해면상뇌증에 대한 국내 소, 사슴, </SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">염소의 유전자분석 및 진단에 관한 연구</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 72.75pt; HEIGHT: 44.62pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>2001～2003</SPAN></P><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>(3년)</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 54.77pt; HEIGHT: 44.62pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>203</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 317.96pt; HEIGHT: 44.62pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 1.7pt solid" vAlign=center><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">∘국내사육 반추수에 대한 정상 프리온 단백질의</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US> </SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">다형성 분석 결과, 한우에서 차이 없음을 확인</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US> </SPAN></P><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">∘</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">전염성해면상뇌증 진단을 위한 면역블로팅법 확립</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US> </SPAN></P></TD></TR><br />
<TR><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 1.7pt solid; WIDTH: 37.96pt; HEIGHT: 29.22pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>2</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 244.55pt; HEIGHT: 29.22pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">전염성해면상뇌증의 원인 프리온 단백질(PrP</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; VERTICAL-ALIGN: super; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>sc</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>) 검출을 위한 ELISA법 개발</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 72.75pt; HEIGHT: 29.22pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>2004～2005</SPAN></P><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>(2년)</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 54.77pt; HEIGHT: 29.22pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>150</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 317.96pt; HEIGHT: 29.22pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 1.7pt solid" vAlign=center><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">∘</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>ELISA 진단에 적합한 항체 개발 및 뇌조직에서</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US> 변형프리온 검출기법 개발 </SPAN></P></TD></TR><br />
<TR><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 1.7pt solid; WIDTH: 37.96pt; HEIGHT: 38.96pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>3</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 244.55pt; HEIGHT: 38.96pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">변형프리온 항원결정 부위 분석 및 프리온특수 세포주 개발연구</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 72.75pt; HEIGHT: 38.96pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>2006～2008</SPAN></P><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>(3년)</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 54.77pt; HEIGHT: 38.96pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>332</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 317.96pt; HEIGHT: 38.96pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 1.7pt solid" vAlign=center><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">∘</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">종 특이성 항체 (3종) 및 진단용 항체 개발</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US> (2종) 및 평가</SPAN></P><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">∘</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">프리온 감염 세포주 확립 (2종) </SPAN></P></TD></TR><br />
<TR><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 1.7pt solid; WIDTH: 37.96pt; HEIGHT: 29.22pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>4</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 244.55pt; HEIGHT: 29.22pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">변형프리온 증폭기법에 관한 연구</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 72.75pt; HEIGHT: 29.22pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>2006～2008</SPAN></P><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>(3년)</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 54.77pt; HEIGHT: 29.22pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>315</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 317.96pt; HEIGHT: 29.22pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 1.7pt solid" vAlign=center><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">∘</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">변형프리온 증폭(PMCA) 기법 확립 </SPAN></P></TD></TR><br />
<TR><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 1.7pt solid; WIDTH: 37.96pt; HEIGHT: 60.02pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>5</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 244.55pt; HEIGHT: 60.02pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">골수에서의 소해면상뇌증(BSE) 병인구명 및</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US> 시험관내 BSE</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; VERTICAL-ALIGN: super; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">주1)</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">원인체 배양모델개발</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 72.75pt; HEIGHT: 60.02pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>2006.10～ 2009.6</SPAN></P><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>(4년)</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 54.77pt; HEIGHT: 60.02pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>180</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 317.96pt; HEIGHT: 60.02pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 1.7pt solid" vAlign=center><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">∘</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>BSE감염소의 흉골 골수는 소에서 감염력이</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US> 인정되지 않음을 확인 </SPAN></P><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">∘</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">국내 생산 항체의 국제적 평가(6종) </SPAN></P><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">∘</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>BSE 지속감염주 세포 확립 </SPAN></P></TD></TR><br />
<TR><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 1.7pt solid; WIDTH: 37.96pt; HEIGHT: 60.02pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>6</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 244.55pt; HEIGHT: 60.02pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">국내 사육소의 BSE 감수성인자 분석 (외부용역) </SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 72.75pt; HEIGHT: 60.02pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>2007</SPAN></P><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>(1년)</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 54.77pt; HEIGHT: 60.02pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>50</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 317.96pt; HEIGHT: 60.02pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 1.7pt solid" vAlign=center><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">∘</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">국내 소품종(한우 및 젖소)에 대한 프리온유전자 분석 및 외</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">국 소품종과 비교 </SPAN></P><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>- 외국종과의 차이가 없음을 확인 </SPAN></P><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>- 프리온 유전자원 24종 확보 </SPAN></P></TD></TR><br />
<TR><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 1.7pt solid; WIDTH: 37.96pt; HEIGHT: 54.36pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>7</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 244.55pt; HEIGHT: 54.36pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">프리온질병 감수성모델개발(외부용역) </SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 72.75pt; HEIGHT: 54.36pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>2007, 2010</SPAN></P><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>(2년)</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 54.77pt; HEIGHT: 54.36pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>140</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 0.28pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 317.96pt; HEIGHT: 54.36pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 1.7pt solid" vAlign=center><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">∘</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">사슴프리온이 과발현된 마우스 생산(2007) &#8211; 프리온 발현량 확인중 (2010)</SPAN></P><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">∘</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">염소와 한우 프리온이 과발현된 마우스 생산예정 (2010)</SPAN></P></TD></TR><br />
<TR><br />
<TD style="BORDER-BOTTOM: #000000 1.7pt solid; BORDER-LEFT: #000000 1.7pt solid; WIDTH: 37.96pt; HEIGHT: 34.67pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>8</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 1.7pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 244.55pt; HEIGHT: 34.67pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">전염성해면상뇌증 감염력 평가 및 진단을 위한 세포 Bioassay 확립</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 1.7pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 72.75pt; HEIGHT: 34.67pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>2009～2011</SPAN></P><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>(3년)</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 1.7pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 54.77pt; HEIGHT: 34.67pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 0.28pt solid" vAlign=center><br />
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>170</SPAN></P></TD><br />
<TD style="BORDER-BOTTOM: #000000 1.7pt solid; BORDER-LEFT: #000000 0.28pt solid; WIDTH: 317.96pt; HEIGHT: 34.67pt; BORDER-TOP: #000000 0.28pt solid; BORDER-RIGHT: #000000 1.7pt solid" vAlign=center><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">∘</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US>BSE 및 CWD</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; VERTICAL-ALIGN: super; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">주2)</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US> 감염력 평가를 위한 감수성</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-fareast-font-family: 한양신명조; mso-hansi-font-family: 한양신명조" lang=EN-US> 세포 개발 완료 </SPAN></P><br />
<P style="LINE-HEIGHT: 140%; LAYOUT-GRID-MODE: char" class=바탕글><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">∘</SPAN><SPAN style="FONT-FAMILY: 한양신명조; FONT-SIZE: 11pt; mso-hansi-font-family: 한양신명조; mso-ascii-font-family: 한양신명조">세포 bioassay 확립은 진행중임 (2010)</SPAN></P></TD></TR></TBODY></TABLE><SPAN style="FONT-FAMILY: 한양중고딕; FONT-SIZE: 12pt; mso-fareast-font-family: 한양중고딕; mso-hansi-font-family: 한양중고딕" lang=EN-US>(단위 : 백만원)</SPAN><br />
<P></P><br />
<P class=바탕글><SPAN style="FONT-FAMILY: 휴먼명조; FONT-SIZE: 12pt; VERTICAL-ALIGN: super; mso-hansi-font-family: HCI Poppy; mso-ascii-font-family: HCI Poppy">주1)</SPAN><SPAN style="FONT-FAMILY: HCI Poppy; FONT-SIZE: 12pt; mso-fareast-font-family: 휴먼명조; mso-hansi-font-family: HCI Poppy" lang=EN-US> BSE (광우병): Bovine Spongiform Encephalitis, </SPAN><SPAN style="FONT-FAMILY: 휴먼명조; FONT-SIZE: 12pt; VERTICAL-ALIGN: super; mso-hansi-font-family: HCI Poppy; mso-ascii-font-family: HCI Poppy">주2)</SPAN><SPAN style="FONT-FAMILY: HCI Poppy; FONT-SIZE: 12pt; mso-fareast-font-family: 휴먼명조; mso-hansi-font-family: HCI Poppy" lang=EN-US> CWD (사슴만성소모성질병): Chronic Weaning Disease</SPAN></P></p>
]]></content:encoded>
			<wfw:commentRss>http://www.chsc.or.kr/?post_type=reference&#038;p=2296/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>[광우병] 안구검사 통해 광우병 검출 가능성 보고</title>
		<link>http://www.chsc.or.kr/?post_type=reference&#038;p=2035</link>
		<comments>http://www.chsc.or.kr/?post_type=reference&#038;p=2035#comments</comments>
		<pubDate>Tue, 08 Jun 2010 12:18:53 +0000</pubDate>
		<dc:creator>건강과대안</dc:creator>
				<category><![CDATA[광우병]]></category>
		<category><![CDATA[식품 · 의약품]]></category>
		<category><![CDATA[BSE]]></category>
		<category><![CDATA[Prion]]></category>
		<category><![CDATA[생체검사]]></category>
		<category><![CDATA[안구검사]]></category>
		<category><![CDATA[인간광우병]]></category>
		<category><![CDATA[프리온]]></category>

		<guid isPermaLink="false">http://www.chsc.or.kr/?post_type=reference&#038;p=2035</guid>
		<description><![CDATA[야콥 페트리시(Jacob Petrich) 박사팀이 안구검사를 통해 광우병에 감염된 소를 검출할 수 있는 새로운 검사방법에 대한 연구결과를 발표했다는 소식입니다. Eye test to detect cattle infected with Mad Cow Disease [...]]]></description>
				<content:encoded><![CDATA[<p><P>야콥 페트리시(Jacob Petrich) 박사팀이 안구검사를 통해 광우병에 감염된 소를 검출할 수 있는 새로운 검사방법에 대한 연구결과를 발표했다는 소식입니다. <BR><BR>Eye test to detect cattle infected with Mad Cow Disease</P><br />
<P>Source:&nbsp; News-Medical-Net 5. June 2010 05:47 <BR><A href="http://www.news-medical.net/news/20100605/Eye-test-to-detect-cattle-infected-with-Mad-Cow-Disease.aspx">http://www.news-medical.net/news/20100605/Eye-test-to-detect-cattle-infected-with-Mad-Cow-Disease.aspx</A><BR>&nbsp;<BR>The eyes may or may not be windows to the soul, as the old adage goes, but scientists are reporting evidence that a peek into the eyes of cattle may become the basis for a long-sought test to detect infection with the agent that causes Mad Cow Disease. That test could help prevent the disease from spreading in the food supply. A study on using the tell-tale glow given off by eyes infected with the Mad Cow agent appears in ACS&#8217; semi-monthly journal Analytical Chemistry. </P><br />
<P>Jacob Petrich and colleagues note that the human form of Mad Cow Disease is linked to eating beef from animals infected with abnormal proteins called prions implicated in a range of brain diseases. Scientists are trying to develop tests to detect infected cattle before they enter the food supply. Past studies suggest that chemical changes in an animal&#8217;s retina, the light sensitive nerve tissue in the back of the eye, may provide a basis for detecting prion diseases.</P><br />
<P>The scientists showed that retinas of sheep infected with scrapie, a disease similar to Mad Cow Disease, emit a characteristic glow when examined with a beam of light from a special instrument. They suggest that eye tests based on the finding could become important in the future for fast, inexpensive diagnosis of prion diseases and other neurological diseases. </P><br />
<P>Source: American Chemical Society</P></p>
]]></content:encoded>
			<wfw:commentRss>http://www.chsc.or.kr/?post_type=reference&#038;p=2035/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>[광우병] 전염성밍크뇌증(TME) 병인론과 미국의 토착 광우병</title>
		<link>http://www.chsc.or.kr/?post_type=reference&#038;p=891</link>
		<comments>http://www.chsc.or.kr/?post_type=reference&#038;p=891#comments</comments>
		<pubDate>Fri, 24 Jul 2009 13:17:10 +0000</pubDate>
		<dc:creator>건강과대안</dc:creator>
				<category><![CDATA[광우병]]></category>
		<category><![CDATA[식품 · 의약품]]></category>
		<category><![CDATA[L-type BSE]]></category>
		<category><![CDATA[Prion]]></category>
		<category><![CDATA[TME]]></category>
		<category><![CDATA[transmissible mink encephalopathy]]></category>
		<category><![CDATA[미국산 쇠고기 수입]]></category>
		<category><![CDATA[비정형 광우병]]></category>

		<guid isPermaLink="false">http://www.chsc.or.kr/?post_type=reference&#038;p=891</guid>
		<description><![CDATA[밍크의 뇌를 스펀지처럼 파괴하는 전염성 밍크뇌증(TME)의 병인론에 관해 기존의 연구결과들을 검토한 review article입니다. 작고한 마쉬(Marsh RF) 박사는 1960년대부터 미국에서 밍크의 질병을 연구한 학자로 병들거나 죽은 다우너 소를 밍크에게 [...]]]></description>
				<content:encoded><![CDATA[<p><P _nwii="0" XhgXW="0">밍크의 뇌를 스펀지처럼 파괴하는 전염성 밍크뇌증(TME)의 병인론에 관해 기존의 연구결과들을 검토한 review article입니다. 작고한 마쉬(Marsh RF) 박사는 1960년대부터 미국에서 밍크의 질병을 연구한 학자로 병들거나 죽은 다우너 소를 밍크에게 사료로 급여함으로써 전염성 밍크뇌증(TME)이 발생했으며, 미국에서 토착 광우병(BSE)이 아주 오래전부터 존재했다고 주장한 바 있습니다. 이 논문에서도 마쉬 박사의 연구결과들이 많이 인용되어 있습니다.<BR><BR>미국에서 전염성 밍크뇌증(TME)은 1947년 위스콘신주 브라운 카운티의 한 농장에서 미국에서 처음으로 발병했다고 알려졌으며, 1965년 하트소우(Hartsough)와 버거(Burger)가 처음으로 학계에 보고했습니다. 전염성 밍크뇌증(TME)은 1985년 위스콘신주에서 마지막으로 발병한 것으로 알려져 있습니다.<BR><BR>전염성 밍크뇌증(TME)은 경구 감염으로 전염될 수 있는 전염성 해면상 뇌증/프리온 질병(TSE/prion disease)이지만, 그 병인론은 아직까지 확실하게 밝혀지지 않아 불확실한&nbsp;상황입니다. <BR><BR>처음에는 전염성 밍크뇌증(TME)이 스크래피에 감염된 양의 사체나 부산물을 섭취함으로써 발생했다고 생각했으나 오직 한 사례에서만 양(예를 들면 머리)을 원료로 한 제품과 연관관계가 있는 것으로 확인되었습니다. <BR><BR>영국에서 발생한&nbsp;7사례의 스크래피 원인체를 24마리의 어린 밍크에게 뇌내접종(intracerebrally )을 실시한 실험 결과, 오직 1마리에서 24개월 후 전염성 밍크뇌증(TME) 증상이 나타났습니다.<BR><BR>반면 미국에서 발생한 스크래피 원인체를 16마리의 어린 밍크에게 주입한 결과 11~24개월의 잠복기를 거쳐 100% 전염성 밍크뇌증(TME) 증상이 나타났습니다.<BR><BR>1985년 마쉬 박사가 조사한 위스콘신주의&nbsp; Stetsonville의 전염성 밍크뇌증(TME) 사례는 병인론에 대한 하나의 단서를 제공했습니다. 발생 농장에서 밍크에게 투여한 사료는 사료회사에서 상업용으로 판매하는 사료(예를 들면 조류, 어류, 시리얼)와 밍크농장에서 50마일 반경에 있는 젖소 농장에서 병들거나 다우너 증상을 보이는 젖소에서 유래한 싱싱한 살코기(신선육)이었습니다. 이로써 BSE(광우병)와 전염성 밍크뇌증(TME)의 연관관계가 밝혀진 것입니다.<BR><BR>소와 밍크가 종간 장벽을 뛰어넘어 전염성 해면상 뇌증(또는 프리온 질병)에 감염된다는 사실은 실험적으로 확인되었고, 추가적인 연구에서 전염성 밍크뇌증(TME)이 전형적인 광우병 변형 프리온보다 낮은 분자량을 특징적으로 보이는&nbsp;L-type BSE와 유사한 증상을 보인다는 사실도 밝혀졌습니다.<BR><BR>결국 이러한 실험결과에 근거해서 비판적인 과학자들은 미국의 광우병 위험이 축소되어 알려졌으며, 미국에서는 적어도 1960년 이전부터 토착적인 광우병이&nbsp;광범위하게&nbsp;발생하고 있었다는&nbsp;주장을 지속적으로 제기했던 것입니다.<BR><BR>보다 자세한 내용은 첨부한 폴란드와 미국학자들이 공동으로 작성한 리뷰 논문 파일 전문을 통해 확인하시기 바랍니다.<BR><BR>======================================================<BR><BR><FONT size=3><STRONG>Transmissible mink encephalopathy – review of the etiology</STRONG></FONT><br />
<P _nwii="0" XhgXW="0">출처 : Folia Neuropathol 2009; 47 (2): 195-204 <BR>http://www.termedia.pl/showpdf.php?article_id=12696&#038;filename=Transmissible.pdf&#038;priority=1<BR><BR>Paweł P. Liberski1, Beata Sikorska1, Don Guiroy2, Richard A. Bessen3<BR><BR>1Department of Molecular Pathology and Neuropathology, Medical University Lodz, Poland; 2Natividad Medical Center, Salinas, California;<BR>Monterey County Behavioral Health, Salinas, California, USA, 3Veterinary Molecular Biology, Montana State University Bozeman, USA<BR><BR>A b s t r a c t<BR><BR>We review here the history, neuropathology, clinical picture and molecular data on transmissible mink encephalopathy (TME). This obscure disease is of utmost importance as it is plausible that it represents a transmission of hidden bovine spongiform encephalopathy (BSE) to mink in the USA. Of special interest is the similarity of L-type of BSE and TME. Furthermore, experimental molecular studies showed the TME strain-specific in vitro conversion in a cell-free system. In addition, we show here for the first time confocal laser microscopy studies of co-localization of PrPd- amyloid plaques and GFAP-expressing astrocytes.<BR><BR></P><br />
<P _nwii="0" XhgXW="0">History of TME<br />
<P _nwii="0" XhgXW="0">Transmissible mink encephalopathy (TME) is a rare disease of ranch-reared mink (Mustela vision) (Fig. 1) described in 1965 by Hartsough and Burger [15,28]. The first outbreak was noticed in 1947 in a farm in Brown County, Wisconsin, USA and fatality reached almost 100% of the adult mink. Insight into the nature of infection was evident when over 100 pregnant dams sent to another farm in Winona County eventually developed TME, but mink at the recipient ranch did not. This was the first indication that TME was self-limiting and had an incubation period of at least six months. A second TME outbreak occurred simultaneously in several farms in Sheboygan, Calumet and Manitowoc Counties, Wisconsin in 1961. Symptoms were similar to the first outbreak, but the prevalence of TME was limited to 10 to 30% of adult mink among the farms [35]. All of the affected farms were using a ready-mix feed prepared at a common feed plant, demonstrating that TME was likely due to an orally acquired infectious agent. This was followed by another outbreak in 1963 in Sawyer County. A similar pattern emerged with nearly 100% of the 1,100 adult mink affected, but the 4,500 kits did not develop symptoms of TME. There was no evidence of vertical transmission, even to kits that nursed on dams with advanced TME. The term “transmissible mink encephalopathy” was subsequently introduced by Marsh et al. [34] to describe this disease that primarily affects adult mink over one year of age, has an incubation period of at least 6 months, and clinical and neuropathological similarities to scrapie, a fatal neurodegenerative disease in sheep. Fewer than a dozen additional outbreaks of TME have been described in Canada, East Germany, Finland, and the former Soviet Union [1].<br />
<P _nwii="0" XhgXW="0">The last outbreak of TME was described in 1985 in Stetsonville, Wisconsin, USA [32] and more than 4,300 out of 7,300 adult mink developed TME over a 5-month period, but 600 blue iris kits purchased six months prior to the onset of TME or kits born at this ranch were not affected. This pattern was consistent with previous outbreaks in which exposure to prion/ TSE infection took place from 6 to 12 months prior to clinical symptoms, was due to a single exposure of infection, and affected a large number of mink.<br />
<P _nwii="0" XhgXW="0">Etiology<br />
<P _nwii="0" XhgXW="0">TME is an orally acquired TSE/prion disease, but the etiology is uncertain. TME was initially thought to be transmitted by consumption of sheep carcasses or by-products due to similarities between the diseases, but only in one case were sheep products (e.g., heads) linked to mink diet. Although it cannot be conclusively demonstrated that sheep products were not the source of TME, the inclusion of sheep products in mink feed was demonstrated only rarely [35]. Experimental inoculation of mink with several isolates of scrapie resulted in a few examples of transmission to mink in which the distribution of spongiform lesions was similar to natural TME [39]. Seven sources of scrapie from the U.K. were intracerebrally inoculated into 24 mink kits, but only one mink developed TME after 22 months. Three U.S. scrapie isolates inoculated into 16 kits resulted in 100% penetrance with incubation periods ranging from 11 to 24 months. While this indicates that mink are susceptible to TME, it also suggests that the isolates tested were not likely to be the origin of TME since incubation periods are typically less than one year in natural TME. This indicated that either a subset of scrapie strains are the causative agent of TME or that there is an additional unrecognized source of TME.<br />
<P _nwii="0" XhgXW="0">A possible clue was provided during the Stetsonville TME outbreak in which the rancher fed his mink commercial feed (e.g., poultry, fish, cereal) and fresh meat primarily from sick or downer dairy cattle within a 50-mile radius of his ranch [37]. He did not recall including sheep products in his homemade feed ration. Upon reviewing prior TME outbreaks in the U.S. and Canada, in all four cases in which records were available and were not linked to a commercial feed plant, downer cattle were also included in the mink diet. The Stetsonville TME isolate, and subsequently additional TME isolates, were transmitted to cattle by intracerebral inoculation and the Stetsonville TME isolate was the first confirmed case of experimental transmission of a TSE/prion disease to cattle. What was striking was that upon experimental transmission of cattle TME back into mink by the oral and intracerebral routes, the incubation periods were similar to that found for mink passaged TME. Hence, the pathogenicity of the Stetsonville TME agent in mink was not altered upon passage into cattle, suggesting that a previously unrecognized TSE/prion disease in cattle may be the source of TME infection. Additional studies strongly suggest that TME has similarities to L-type BSE in transgenic mice compared to H-type or classical BSE [2]. Since the L-type BSE does not appear to be an infectious form of TSE/prion disease, the proposal by Marsh [35,37] that a rare TSE in cattle may be the source of TME infection seems plausible. This is particularly the case in Wisconsin, which has had the majority of TME in the USA and is a prominent dairy state with aged cattle being a primary source of fresh meat for mink ration. Since mink are a sentinel host it is not surprising that they may have been a key host in amplifying a rare cattle TSE disease. Another possible explanation for the high incidence of TME in Wisconsin is based on the recent identification of a mutation in the prion protein gene in cattle with atypical BSE. There may be cattle breeding stock in Wisconsin that carry a mutation in the prion protein gene that is linked to late onset disease and are also the source of TSE infection for mink TME outbreaks described in the 1960s and 1985.<br />
<P _nwii="0" XhgXW="0">To this end, mink were shown to be sensitive to scrapie [23,24]. Of interest, following i.c. inoculation with the UK source of scrapie from a Suffolk sheep only a single animal developed the disease. In contrast, American sources B-834 and B-957 from Suffolk sheep readily transmitted to mink. Also, in another outbreak of TME in Stetsonville, Wisconsin, USA, the affected mink were apparently fed with downer cattle but not scrapie-affected sheep [32], and thus TME may result from BSE transmission from cattle to mink [37]. TME is readily transmitted to cattle [26]. The suggestion that TME may result from transmission from infected cattle but not sheep was supported by recent data on phenotypic similarities of TME in cattle and L-type bovine spongiform encephalopathy (BSE) transmitted to ovine transgenic mice (TgOvPrP4) [2]. To this end, L-type of BSE and TME in TgOvPrP4 presented similar molecular mass of all 3 bands of PrPd. Unglycosylated PrPd in L-type BSE, bovine TME and typical BSE has the same molecular mass of approximately 18 kDa in contrast to that of diglycosylated PrPd species which was lower by 0.5-0.8 kDa in L-type BSE and bovine TME as compared to typical BSE. Furthermore, L-type BSE and bovine TME transmitted to TgOvPrP4 mice presented spongiform change of low intensity but PrPd was strongly expressed including amyloid plaques. Mink were also susceptible to BSE [44]. Exposure by the oral route was ineffective but Marsh and Hanson [35] cited Gajdusek [20] who, in turn, suggested that not the oral route as such but skin and mucosa abrasion are the real port of entry of the agent. The hypothesis was tested experimentally by subcutaneous inoculation of pastel mink with the Idaho source of TME [23]. The infectivity spread from the lymph nodes draining the site of the inoculation (1-4 weeks postinoculation, PI), through the other lymph nodes (98-12 weeks PI, the level 103.0 – 4.0 LD50) to the nervous system stage at 20 week PI (103.0 – 4.5 LD50) to reach the maximum at approximately 28 weeks PI. The sciatic nerve was first affected. The infectivity was detected in both the blood and the thymus, which suggests blood-borne infection. Analogously to scrapie, when the HY TME agent was inoculated into sciatic nerves, hamsters segregated into 2 groups – with a short and a long incubation time [5]. PrPd was first detected in the thoracic spinal cord and then spread rostrally toward the cervical cord. In the brain, PrPd was first detected in the red nucleus, first unilaterally and then bilaterally.<br />
<P _nwii="0" XhgXW="0">Clinical and neuropathological studies in mink<br />
<P _nwii="0" XhgXW="0">Clinical description<br />
<P _nwii="0" XhgXW="0">In the first report by Hartsough and Burger [28], the clinical symptomatology of TME was described in detail. The onset was insidious and animals lost their cleanliness and soiled the boxes with urine and feces. Difficulties in swallowing and eating, excitability and tail arching over the back were noticed. Incoordination followed and typical “jerky stepping action of the hind legs” developed along with epileptic seizures and self-mutilation. The clinical course was longer in females (2 to 6 weeks) than males.<br />
<P _nwii="0" XhgXW="0">Neuropathology and immunohistochemistry<br />
<P _nwii="0" XhgXW="0">The first description of TME neuropathology was also descried by Hartsough and Burger [28], who noticed neuronal degeneration and spongiform change (Figs. 2-4). Those authors also stressed similarities with scrapie. However, in TME transmitted to aged mink of the Chediak-Higashi genotype, the spongiform change may be minimal or even absent [40].<br />
<P _nwii="0" XhgXW="0">Eckroade et al. [10] described the topography of lesions in experimental TME and the sequential development of those lesions following intracerebral inoculation with TME. The incubation period was approximately 31-33 weeks. Spongiform change was severe in the cerebral cortex and an anterior-posterior gradient was observed; the most severe vacuolation was seen in the gyri bordering the cruciate sulcus and within the anterior and the posterior sigmoid gyrus. In the posterior part of the brain, the lesions were minimal. The other parts of the telencephalon were severely affected – caudate nucleus, anterior olfactory tubercle, septal nuclei and putamen – while the globus pallidus was less affected. The diencephalon was affected severely and the hypothalamus was more uniformly vacuolated than the thalamus. The mesencephalon was vacuolated, especially the periaqueductal gray matter. The red nucleus was affected by bizarre intraneuronal vacuoles of great size. The pons, medulla and spinal cord were affected moderately at least.<br />
<P _nwii="0" XhgXW="0">The earliest spongiform change were observed in the anterior part of the brain 24 weeks postinoculation, sometimes as isolated foci of vacuolation in the cerebral cortex (along the cruciate sulcus) and the thalamus. The caudate nucleus, the periaqueductal gray matter, the central tegmental field of the mesencephalon and the pons were affected minimally at first. Then, spongiform change spread to other neuroanatomical areas; the spreading along the cruciate sulcus was the most rapid.<br />
<P _nwii="0" XhgXW="0">As already mentioned, from the original Stetsonville TME inoculum, two different strains of TME emerged, i.e. HY and DY, and they differ by topography of lesions [32].The HY strain was characterized by moderate to severe spongiform change in the brain stem, the granule layer of the cerebellum, thalamus, the basal ganglia and the cerebral cortex. In contrast, the DY strain exhibited less severe spongiform change in the brain stem and the cerebellum but more intense vacuolation in the cerebral cortex. The most characteristic lesion of the DY strain in hamsters was focal accumulation of large vacuoles surrounding the pyramidal cell layer of the hippocampus.<br />
<P _nwii="0" XhgXW="0">The first immunohistochemical studies of TME were published from the laboratory of Gajdusek [2], who used TME-affected mink, TME-infected golden Syrian hamsters and TME-affected squirrel monkeys and ferrets. In sections stained routinely with H &#038; E, typical spongiform change are visible (Fig. 5). Immunohistochemistry for GFAP revealed abundant reactive astrocytic gliosis (Figs. 6-11). Anti-PrP antibodies revealed many different forms of misfolded PrP deposits: plaques (Fig. 9), perineuronal (Fig. 10) and subependymal (Fig. 11) deposits as well as diffuse staining in the cerebellum (Fig. 12) and the hippocampal formation (Fig. 13).<br />
<P _nwii="0" XhgXW="0">Laser confocal microscopy<br />
<P _nwii="0" XhgXW="0">Double labeling for both PrPSc and GFAP revealed co-localization of both proteins (Figs. 14-15). For immunofluorescent labeling and multichannel confocal microscopy we used mouse anti-PrP monoclonal antibody (clone 3F4, DAKO, Denmark, dilution 1 : 300) and rabbit anti-GFAP polyclonal antibody (DAKO, Denmark, dilution 1:250). The fluorescent-labeled secondary antibody for the anti-PrP was Alexa Fluor 488 goat anti-mouse IgG (Molecular Probes, USA, 1 : 200) and for anti-GFAP Alexa Fluor 546 goat anti-rabbit IgG (Molecular Probes, 1 : 200). Immunofluorescence labeling was evaluated using an Olympus FluoView1000 laser scanning confocal microscope.<br />
<P _nwii="0" XhgXW="0">Transmission to different species<br />
<P _nwii="0" XhgXW="0">The first transmission of TME from mink to mink using intramuscular inoculation, with the incubation period of 183 to 197 days, was performed by Burger and Hartsough [15,28]. Mink infected orally also developed TME. Neuropathological examination revealed astrocytosis and spongiform change. Of note, using filtration, the size of the infectious agent was estimated to be lower than 500 nm.<br />
<P _nwii="0" XhgXW="0">TME is transmissible to several mammalian species. TME is transmissible to sheep and goats [23], hamsters [36,38], skunks, ferrets and raccoons [17,25,27], American sable (pine marten) and beech marten [26], and squirrel monkeys [18]. The transmission of TME from the Stetsonville source to ferrets resulted in a long incubation period of 28 to 38 months on the primary, and 8 to 9 months on the secondary passage [6]. In contrast, TME was never transmitted to mice [10,34,36,45]. However, TME is readily transmitted to transgenic mice with mink PrP gene [45]. Kimberlin et al. [29] isolated two strains of TME in Chinese hamsters (333K and 333W) that were readily discriminated by the incubation time (130 and 230 days, respectively).<br />
<P _nwii="0" XhgXW="0">Cloning of the PRNP gene in mink and ferrets<br />
<P _nwii="0" XhgXW="0">The gene encoding for PrPTME was cloned by Kretzschmar et al. [31]. The open reading frame (ORF) consists of 770 nucleotides (nts) follow by a 3’ untranslated sequence of 1650 nt. The deduced mink PrPTME consists of 257 amino acids (aa); the first 24 aa form a signal peptide. There are two Asp glycosylation sites at positions 185 and 201. Of interest, the “anti-PrP” sequence on the anti-sense DNA strand is interrupted by several stop codons, in contrast to the “anti-PrP” sequence of several other species. The closest species of the mustelids belonging to the weasel family are ferrets, whose PrP gene is one nt longer than that of the mink gene [6]. There are seven differences between ferret and mink PrP gene – 84 (C to A); 231(A to T); 327 (T to C); 354 (T to A), 375 (T to C); 671 (A to G) and 747 (G to A) – but only two differences at the level of aa: 179 (Leu to Phe) and 224 (Glu to Arg).<br />
<P _nwii="0" XhgXW="0">Molecular biology of TME<br />
<P _nwii="0" XhgXW="0">The early studies by Marsh et al. [36,41] and others [14] confirmed that the physicochemical properties of the TME agent are similar to those of the scrapie agent. In particular, the TME agent is resistant to formalin: after 4-month exposure the titer dropped from 104.8 ip LD50/ml to 106.5 ip LD50/ml and to 103.8 ip LD50/ml following 20 months.<br />
<P _nwii="0" XhgXW="0">Molecular basis of TME strain diversity<br />
<P _nwii="0" XhgXW="0">Experimental transmission of Stetsonville TME into Syrian golden hamsters resulted in the identification of two hamster TME strains upon the third serial passage [33]. One strain had an incubation period of 65 days and was characterized by hyper-excitability (HY TME strain) and tremor of the head and shoulders, while DY (drowsy) TME strain caused progressive lethargy and drowsiness beginning at 168 days post-inoculation. The HY TME strain replicated to a 100-fold higher titer than the DY TME strain in hamster brain, while following additional serial passage, the DY TME strain remained pathogenic upon passage into mink, while the HY TME strain lost its pathogenicity in mink. These findings were consistent with the isolation of two distinct strains of the TME agent upon interspecies passage in hamsters. Additional studies demonstrated that either both TME strains were present in the original Stetsonville TME isolate, or that the short incubation HY TME strain arose upon passage into hamsters and was preferentially selected for since it can replicate faster than DY TME. Serial passage of Stetsonville TME into hamsters at a high dilution resulted in isolation of only the DY TME strain, indicating that this was likely the predominant strain isolated from mink.<br />
<P _nwii="0" XhgXW="0">Although the HY and DY TME strains were consistent with previous studies that have identified two or more TSE strains upon interspecies transmission, the TME strains also provided the first clues as to the molecular basis of TSE strain diversity [8,9,11,12]. The molecular profiles of PrPTME polypeptides revealed a 1-2 kDa shift in molecular weight following limited proteinase K (PK) treatment (21 kDa vs. 19 kDa), which removes the PK-sensitive N-terminal portion. N-terminal sequencing revealed that PK cleaved further into the N-terminus of DY TME compared to HY TME, which suggested that the two TME strains may have distinct conformations. Differences in sedimentation properties and relative susceptibility to degradation with PK were consistent with this hypothesis. Infrared spectra of the TME PrPSc demonstrated differences in the b-sheet secondary structure content, providing further evidence that these TSE strains had distinct conformations. The ability of these two distinct PrPSc conformations to self-propagate was also demonstrated in an in vitro assay when they were individually incubated with PrPC and the HY TME PrPSc converted PrPC into a 21 kDa PK-resistant PrP, while DY TME PrPSc converted PrPC into a 19 kDa PK-resistant PrP [7,30]. In this cell-free PrP conversion assay, the kinetics of PK-resistant PrP formation was also different between the TME strains, which was consistent with a strain-specific pattern of PrPTME formation in vivo. Overall, these studies suggested that the molecular basis of TME strain diversity is determined by the strain-specific conformation of PrPTME and that each PrPSc conformation can convert the same PrPC molecule into a strain-specific subunit of the PrPSc fibril or aggregate. The formation of each PrPTME conformation may be preferentially favored under specific cellular or subcellular conditions, and the brain distribution of PrPTME may be partially determined by the preferred sites of strain PrPTME formation. Partial evidence for this is provided by the observation that the DY TME strain does not appear to be able to replicate in secondary lymphoid tissue, while the HY TME strain can replicate in lymph nodes and spleen.<br />
<P _nwii="0" XhgXW="0">Using an in vitro PrPc to PrPd (TME) conversion reaction [7,10,13,30] it was shown that the conversion is “strain-specific”, i.e. HY PrPd only converted PrPc into HY PrPd, and DY PrPd only converted PrPc into DY PrPd. This experiment suggested that certain strain-specificity is encrypted within the conformation of PrPd itself, which, in turn, determines the site of proteinase cleavage and strain-specific size of PrP fragments using Western immunoblot. However, the size of PrPd (either 19 kDa or 21 kDa) is exactly the same as the size of deglycosylated bands purified from human CJD. This may suggest that irrespective of the situation, PrPd may exist only in two major isoforms of 19 kDa and 21 kDa. Whether there are only two strains of every “prion” disease is, in our mind, doubtful.<br />
<P _nwii="0" XhgXW="0">In a separate study, Mulcahy and Bessen [43] found that conversion of PrPc into PrPd consists of three phases – elongation, depolymerization, and steady-stage phase – and that the elongation phase is that in which strain-specific differences are observed. Those differences between HY and DY strains are the total amount of PrPTME and the time when the reaction peaked. Furthermore, a vast difference in the kinetics of PrPTME accumulation was observed in hamster brains infected with either DY or HY TME strains.<br />
<P _nwii="0" XhgXW="0">It seems that both DY and HY TME strains are already present as a mixture in the original Stetsonville inoculum and during subsequent passages undergo selection during interspecies transmission [3]. For instance, one of the 4 clones passaged into Syrian golden hamsters bifurcated into a strain characterized by an incubation period ranging from 219 to 522 days and the PrP banding pattern typical of the DY strain of mink, and a second strain with an incubation period of 219 days and PrP pattern that of the DY strain. Upon further passages into hamsters, the incubation periods decreased, the emerging “strain” presented a mixture of HY and DY strains only on subsequent passages, distinct DY strain emerged, and from that, the HY TME strain was selected.<br />
<P _nwii="0" XhgXW="0">References<br />
<P _nwii="0" XhgXW="0">1. Barlow RM. Transmissible mink encephalopathy: pathogenesis and nature of aetiological agent. J Clin Pathol 1972; 6 (Suppl): 102-109.<br />
<P _nwii="0" XhgXW="0">2. Baron T, Bencsik A, Bicabe A-G, Morignat E, Bessen RA. Phenotypic similarity of transmissible mink encephalopathy in cattle and L-type bovine spongiform encephalopathy in a mouse model. Emerging Inf Dis 2007; 13: 1887-1894.<br />
<P _nwii="0" XhgXW="0">3. Bartz JC, Bessen RA, McKenzie D, Marsh DC, Aiken J. Adaptation and selection of prion protein strain conformations following interspecies transmission of transmissible mink encephalopathy. J Virol 2000; 74: 5542-5547.<br />
<P _nwii="0" XhgXW="0">4. Bartz JC, DeJoia C, Tucker T, Kincaid AE, Bessen RA Extraneural prion neuroinvasion without lymphoreticular system infection. J Virol 2005; 79: 11858-11863.<br />
<P _nwii="0" XhgXW="0">5. Bartz JC, Kincaid RA, Bessen RA. Retrograde transport of transmissible mink encephalopathy within descending motor tracts. J Virol 2002; 76: 5759-5768.<br />
<P _nwii="0" XhgXW="0">6. Bartz JC, Mckenzie DI, Bessen RA, Marsh RF, Aiken JM. Transmissible mink encephalopathy species barrier effect between ferret and mink: PrP gene and protein analysis. J Gen Virol 1994; 75: 2947-2953.<br />
<P _nwii="0" XhgXW="0">7. Bessen RA, Kocisko DA, Raymond GJ, Nandan S, Lansbury PT, Caughey B. Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature 1995; 22: 698-700.<br />
<P _nwii="0" XhgXW="0">8. Bessen RA, Marsh RF. Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent. J Virol 1994; 66: 2096-2101.<br />
<P _nwii="0" XhgXW="0">9. Bessen RA, Marsh RF. Distinct PrP properties suggest the molecular basis for strain variation in transmissible mink encephalopathy. J Virol 1994; 68: 7859-7868.<br />
<P _nwii="0" XhgXW="0">10. Bessen RA, Marsh RF. Identification of two biologically distinct strains of transmissible mink encephalopathy in hamsters. J Gen Virol 1992; 73: 329-334.<br />
<P _nwii="0" XhgXW="0">11. Bessen RA, Marsh RF. Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent. J Virol 1992; 66: 2096-2101.<br />
<P _nwii="0" XhgXW="0">12. Bessen RA, Marsh RF. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J Virol 1994; 68: 7859-7868.<br />
<P _nwii="0" XhgXW="0">13. Bessen RA, Raymond GJ, Caughey B. In situ formation of protease-resistant prion protein in transmissible spongiform encephalopathy-infected brain slices. J Biol Chem 1997; 272: 15227-15231.<br />
<P _nwii="0" XhgXW="0">14. Burger D, Gorham JR. Observation on the remarkable stability of transmissible mink encephalopathy virus. Res Vet Sci 1977; 22: 131-132.<br />
<P _nwii="0" XhgXW="0">15. Burger D, Hartsough GR. Transmissible Encephalopathy of Mink. In: Gajdusek DC, Gibbs CJ Jr, Alpers MP (eds.). NINDB Monograph No.2, Slow, Latent and Temperate Virus Infections. US DEPT of Health, Education, and Welfare, Washington 1965; pp 297-306.<br />
<P _nwii="0" XhgXW="0">16. Caughey B, Raymond GR, Bessen RA Strain-dependent differences in beta-sheet conformations of abnormal prion protein. J Biol Chem 1998; 273: 32230-32235.<br />
<P _nwii="0" XhgXW="0">17. Eckroade RJ, ZuRhein GM, Hanson RP. Transmissible mink encephalopathy in carnivores: clinical, light, and electron microscopic studies in raccoons, skunks, and ferrets. J Wildlife Dis 1973; 9: 229-239.<br />
<P _nwii="0" XhgXW="0">18. Eckroade RJ, ZuRhein GM, Marsh CD, Hanson RP. Transmissible mink encephalopathy: experimental transmission to the squirrel monkey. Science 1970; 169: 1088-1090.<br />
<P _nwii="0" XhgXW="0">19. Ecroade RJ, ZuRhein GM, Hanson RP. Experimental transmissible mink encephalopathy: Brain lesions and their sequential development on mink. In: Prusiner SB, Hadlow WJ (eds.). Slow Transmissible Diseases of the Nervous System, Vol. 1, Academic Press, New York; 409-449.<br />
<P _nwii="0" XhgXW="0">20. Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. Science 1977; 197: 943-960.<br />
<P _nwii="0" XhgXW="0">21. Guiroy DC, Marsh RF, Yanagihara R, Gajdusek DC. Immunolocalization of scrapie amyloid in non-congophilic, non-birefringent deposits in golden Syrian hamsters with experimental transmissible mink encephalopathy. Neurosci Letters 1993; 155: 112-115.<br />
<P _nwii="0" XhgXW="0">22. Hadlow WJ, Race RE, Kenendy RC. Temporal distribution of transmissible mink encephalopathy virus in mink inoculate subcutaneously. J Virol 2004; 61: 3235-3240.<br />
<P _nwii="0" XhgXW="0">23. Hadlow WJ, Race RE, Kenendy RC. Experimental infection of sheep and goats with transmissible mink encephalopathy virus. Can J Vet Res 1987; 51: 135-144.<br />
<P _nwii="0" XhgXW="0">24. Hadlow WJ, Race RE. Cerebroscortical degeneration in goats inoculated with mink-passaged scrapie virus. Vet Pathol 1986; 23: 543-549.<br />
<P _nwii="0" XhgXW="0">25. Hamir AN, Heidel JR, Picton R, Rupprecht CE. Neuronal vacuolation in raccoons (Procyon lotor). Vet pathol 1997; 34: 250-252.<br />
<P _nwii="0" XhgXW="0">26. Hamir AN, Kunkle RA, Miller JM, Bartz JC, Richt JA. First and second cattle passage of transmissible mink encephalopathy by intracerebral inoculation. Vet Pathol 2006; 43: 118-126.<br />
<P _nwii="0" XhgXW="0">27. Hamir AN, Miller JM, O’Rourke KI, bartz JC, Stack MJ, Chaplin MJ. Transmission of transmissible mink encephalopathy to raccoons (Procyon lotor) by intracerebral inoculation. J Vet Diagn Invest 2004: 16: 57-63.<br />
<P _nwii="0" XhgXW="0">28. Hartsough GR, Burger D. Encephalopathy in mink. I. Epizootiologic and clinical observations. J Inf Dis 1965; 115: 387-392.<br />
<P _nwii="0" XhgXW="0">29. Kimberlin RH, Cole S, Walker CA. Transmissible mink encephalopathy (TME) in Chinese hamsters: identification of two strains of TME and comparisons with scrapie. Neuropathol appl Neurobiol 1975; 12: 197-206.<br />
<P _nwii="0" XhgXW="0">30. Kocisko DA, Come JH, Priola SA, Chesebro B, Raymond GJ, Lansbury PT, Caughey B. Cell-free formation of protease-resistant prion protein. Nature 1994; 370: 471-4<br />
<P _nwii="0" XhgXW="0">31. Kretzschmar HA, Neumann M, Riethmüller G, Prusiner SB. Molecular cloning of a mink prion protein gene. J Gen Virol 1992; 73: 2757-2761.<br />
<P _nwii="0" XhgXW="0">32. Marsh RF, Bessen RA, Lehmann S, Hartsough GR Epidemiological and experimental studies on a new incident of transmissible mink encephalopathy. J Gen Virol 1991; 72: 589-594.<br />
<P _nwii="0" XhgXW="0">33. Marsh RF, Bessen RA. Physicochemical and biological characterizations of distinct strains of transmissible mink encephalopathy. Phil Trans Roy Soc London: Biol Sci 1994; 343: 413-414.<br />
<P _nwii="0" XhgXW="0">34. Marsh RF, Burger D, Eckroade R, ZuRhein GM, Hanson RP. A preliminary report on the experimental host range of the transmissible mink encephalopathy agent. J Inf Dis 1969; 120: 713-719.<br />
<P _nwii="0" XhgXW="0">35. Marsh RF, Hanson RP. On the origin of transmissible mink encephalopathy. In: Prusiner SB, Hadlow WJ (eds.). Slow Transmissible Diseases of the Nervous System, Vol. 1, Academic Press, New York; pp. 451-460.<br />
<P _nwii="0" XhgXW="0">36. Marsh RF, Hanson RP. Physical and chemical properties of the transmissible mink encephalopathy agent. J Virol 1969; 3: 176-180.<br />
<P _nwii="0" XhgXW="0">37. Marsh RF, Hartsough GR. Is there a scrapie-like diseases in cattle? In: Proc. of the 89th Annual Meeting of the US Animal Health Ass 1969; pp. 8-9.<br />
<P _nwii="0" XhgXW="0">38. Marsh RF, Kimberlin RH. Comparison of scrapie and transmissible mink encephalopathy in hamsters. II. Clinical signs, pathology and pathogenesis. J Inf Dis 1975; 131: 104-110.<br />
<P _nwii="0" XhgXW="0">39. Marsh RF, Semancik JS, Medappa KC, Hanson RP, Rueckert RR. Scrapie and transmissible mink encephalopathy: search for infectious nucleic acid. J Virol 1974; 13: 993-996.<br />
<P _nwii="0" XhgXW="0">40. Marsh RF, Sipe JC, Morse SS, Hanson RP. Transmissible mink encephalopathy. Reduced spongiform degeneration in aged mink of the Chediak-Higashi genotype. Lab Invest 1976; 34: 381-386.<br />
<P _nwii="0" XhgXW="0">41. Marsh RF. Animal model of human disease. Kuru, Creutzfeldt-Jakob disease (Slow Virus Infection. Am J Pathol 1972; 69: 209-212.<br />
<P _nwii="0" XhgXW="0">42. Mckenzie D, Bartz JC, Marsh DC. Transmissible mink encephalopathy. Sem Virol 1996; 7: 201-206.<br />
<P _nwii="0" XhgXW="0">43. Mulcahy ER, Bessen RA. Strain-specific kinetics of prion protein formation in vitro and in vivo. J Biol Chem 2004; 279: 1643-1649.<br />
<P _nwii="0" XhgXW="0">44. Robinson MM, Hadlow WJ, Huff TP, Wells GAH, Dawson M, Marsh DC, Gorham JR. Experimental infection of mink with bovine spongiform encephalopathy. J Gen Virol 1994; 75: 2151-2155.<br />
<P _nwii="0" XhgXW="0">45. Taylor DM, Dickinson AG, Fraser H, Marsh RF. Evidence that transmissible mink encephalopathy agent is biologically inactive in mice. Neuropathol appl Neurobiol 1986; 12: 207-215.<br />
<P _nwii="0" XhgXW="0">46. Windl O, Buchholz M, Neubauer AN, Schulz-Schaeffer W, Groschup M, Walter S, Arendt A, Neumann M, Voss AK, Kretzschmar HA. Breaking an absolute species barrier: transgenic mice expressing the mink PrP gene are susceptible to transmissible mink encephalopathy. J Virol 2005; 79: 14971-14975.</P></p>
]]></content:encoded>
			<wfw:commentRss>http://www.chsc.or.kr/?post_type=reference&#038;p=891/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
